Kazia Therapeutics Limited (KZIA)

Market Cap	26.46M
Revenue (ttm)	1,372
Net Income (ttm)	-16.92M
Shares Out	25.69M
EPS (ttm)	-1.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,646
Open	0.98
Previous Close	0.98
Day's Range	0.94 - 1.03
52-Week Range	0.50 - 1.68
Beta	2.10
Analysts	Strong Buy
Price Target	2.00 (+94.18%)
Earnings Date	Oct 16, 2023

About KZIA

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 6, 1999
• Country: Australia
• Stock Exchange: NASDAQ
• Ticker Symbol: KZIA

Financial Performance

In 2022, KZIA's revenue was 27,000, a decrease of -99.82% compared to the previous year's 15.23 million. Losses were -24.65 million, 192.7% more than in 2021.

Financial numbers in AUD

Analyst Forecast

According to one analyst, the rating for KZIA stock is "Strong Buy" and the 12-month stock price forecast is $2.0.

Price Target

$2.0

(94.18% upside)

Analyst Consensus: Strong Buy